Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
108M
-
Number of holders
-
133
-
Total 13F shares, excl. options
-
56M
-
Shares change
-
-1.87M
-
Total reported value, excl. options
-
$815M
-
Value change
-
-$39.8M
-
Put/Call ratio
-
0
-
Number of buys
-
72
-
Number of sells
-
-56
-
Price
-
$14.54
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) as of Q4 2021
157 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share as of Q4 2021.
Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) has 133 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56M shares
of 108M outstanding shares and own 51.71% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (5.54M shares), VR Adviser, LLC (4.56M shares), BlackRock Inc. (4.08M shares), Rock Springs Capital Management LP (3.86M shares), Foresite Capital Management IV, LLC (3.4M shares), VANGUARD GROUP INC (2.72M shares), COMMODORE CAPITAL LP (2.67M shares), Holocene Advisors, LP (2.06M shares), BVF INC/IL (1.7M shares), and RENAISSANCE TECHNOLOGIES LLC (1.68M shares).
This table shows the top 133 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.